In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China | Zendy

Shuwen Deng | Zendy; Saham Ansari | Zendy; Macit İlkit | Zendy; Haleh Rafati | Zendy; Mohammad Taghi Hedayati | Zendy; Mojtaba Taghizadeh Armaki | Zendy; Ayatollah Nasrollahi Omran | Zendy; Ali Tolooe | Zendy; Ping Zhan | Zendy; Wanqing Liao | Zendy; Henrich A. van der Lee | Zendy; Paul E. Verweij | Zendy; Seyedmojtaba Seyedmousavi | Zendy

Open Access

In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China

Author(s) -

Shuwen Deng,

Saham Ansari,

Macit İlkit,

Haleh Rafati,

Mohammad Taghi Hedayati,

Mojtaba Taghizadeh Armaki,

Ayatollah Nasrollahi Omran,

Ali Tolooe,

Ping Zhan,

Wanqing Liao,

Henrich A. van der Lee,

Paul E. Verweij,

Seyedmojtaba Seyedmousavi

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01753-16

Subject(s) - tinea capitis , antifungal , microbiology and biotechnology , trichophyton , biology , fluconazole , in vitro , antifungal drugs , traditional medicine , medicine , genetics , botany

Trichophyton schoenleinii is an anthropophilic dermatophyte mainly causing tinea favosa of the scalp in certain regions of the world, especially Africa and Asia. We investigated the in vitro susceptibilities of 55 T. schoenleinii isolates collected over the last 30 years from Iran, Turkey, and China to 12 antifungals using the CLSI broth microdilution method. Our results revealed that terbinafine and ketoconazole were the most potent antifungal agents among those tested, independently of the geographic regions where strains were isolated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research